---
title: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole
  for Early Breast Cancer in Routine Clinical Care - The PreFace Study
date: '2024-02-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38344045/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240212170601&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The risk profile of postmenopausal BC patients selected
  for a five-year upfront letrozole therapy showed a moderate recurrence and death
  risk. However, in subgroups with unfavorable risk factors, prognosis warrants an
  improvement, which might be achieved with novel targeted ...'
disable_comments: true
---
CONCLUSIONS: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted ...